FDA Approves Merck's New Drug For A Rare Lung Disease : vima

The pharmaceutical giant’s new treatment, sotatercept, showed significant benefits for the thousands of patients suffering from pulmonary arterial hypertension in clinical trials.

Related Keywords

United States , Americans , Panagis Galiatsatos , Eliav Barr , Johns Hopkins School Of Medicine , Drug Administration , Johns Hopkins School , New England Journal , New Medication To Prevent , Common Hospital , Fda , Food And Drug Administration , Merck , Pulmonary Arterial Hypertension , Pah , Sotatercept , Winrevair , Lung Disease ,